Cargando…

Evaluation of a connexin-based peptide for the treatment of age-related macular degeneration

A critical target in age-related macular degeneration (AMD) is the retinal pigment epithelium (RPE), which forms the outer blood-retina barrier (BRB). RPE-barrier dysfunction might result from the disruption of intercellular tight junctions (TJs). A Connexin43 (Cx43)-based peptide, aCT1, has been sh...

Descripción completa

Detalles Bibliográficos
Autores principales:	Obert, Elisabeth, Grek, Christina, Ghatnekar, Gautam, Rohrer, Bärbel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9660603/ https://www.ncbi.nlm.nih.gov/pubmed/36387470 http://dx.doi.org/10.1016/j.heliyon.2022.e11359

Ejemplares similares

Systemic Inflammation by Collagen-Induced Arthritis Affects the Progression of Age-Related Macular Degeneration Differently in Two Mouse Models of the Disease
por: Schnabolk, Gloriane, et al.
Publicado: (2020)

Connexin 43-Based Therapeutics for Dermal Wound Healing
por: Montgomery, Jade, et al.
Publicado: (2018)

The Effect of a Connexin43-Based Peptide on the Healing of Chronic Venous Leg Ulcers: A Multicenter, Randomized Trial
por: Ghatnekar, Gautam S, et al.
Publicado: (2015)

Targeting connexin 43 with α–connexin carboxyl-terminal (ACT1) peptide enhances the activity of the targeted inhibitors, tamoxifen and lapatinib, in breast cancer: clinical implication for ACT1
por: Grek, Christina L, et al.
Publicado: (2015)

The Role of the Immune Response in Age-Related Macular Degeneration
por: Whitcup, Scott M., et al.
Publicado: (2013)

Exploring the Therapeutic Potential of Elastase Inhibition in Age-Related Macular Degeneration in Mouse and Human
por: Navneet, Soumya, et al.
Publicado: (2023)

Increased Nonexudative Age-Related Macular Degeneration Diagnosis Among Medicare Beneficiaries With Rheumatoid Arthritis
por: Schnabolk, Gloriane, et al.
Publicado: (2019)

Regulatable Complement Inhibition of the Alternative Pathway Mitigates Wet Age-Related Macular Degeneration Pathology in a Mouse Model
por: Parsons, Nathaniel B., et al.
Publicado: (2023)

Impact of the Controlled Release of a Connexin 43 Peptide on Corneal Wound Closure in an STZ Model of Type I Diabetes
por: Moore, Keith, et al.
Publicado: (2014)

Connexin 43 confers chemoresistance through activating PI3K
por: Pridham, Kevin J., et al.
Publicado: (2022)

Low-Dose Pulsatile Interleukin-6 As a Treatment Option for Diabetic Peripheral Neuropathy
por: Cox, April Ann, et al.
Publicado: (2017)

Age-related macular degeneration: current treatments
por: Hubschman, Jean Pierre, et al.
Publicado: (2009)

Aflibercept for the Treatment of Age-Related Macular Degeneration
por: Trichonas, George, et al.
Publicado: (2013)

Age-related macular degeneration.
por: McConnell, V., et al.
Publicado: (2005)

Age-related macular degeneration
por: Querques, Giuseppe, et al.
Publicado: (2011)

Age-related macular degeneration
por: Mathenge, Wanjiku
Publicado: (2014)

Role of amyloid β-peptide in the pathogenesis of age-related macular degeneration
por: Wang, Minwei, et al.
Publicado: (2021)

Systemic Dendrimer-Peptide Therapies for Wet Age-Related Macular Degeneration
por: Wu, Tony, et al.
Publicado: (2023)

Association of age-related macular degeneration with complement activation products, smoking, and single nucleotide polymorphisms in South Carolinians of European and African descent
por: Rohrer, Bärbel, et al.
Publicado: (2019)

Pegaptanib in the treatment of wet, age-related macular degeneration
por: Vinores, Stanley A
Publicado: (2006)

Treatment of age-related macular degeneration: focus on ranibizumab
por: Spitzer, Martin S, et al.
Publicado: (2008)

Age-related macular degeneration: experimental and emerging treatments
por: Hubschman, Jean Pierre, et al.
Publicado: (2009)

Anecortave acetate in the treatment of age-related macular degeneration
por: Augustin, Albert
Publicado: (2006)

Bevasiranib for the Treatment of Wet, Age-Related Macular Degeneration
por: Garba, Adinoyi O., et al.
Publicado: (2010)

Peptide redesign for inhibition of the complement system: Targeting age-related macular degeneration
por: Mohan, Rohith R., et al.
Publicado: (2016)

Role of Adiponectin Peptide I (APNp1) in Age-Related Macular Degeneration
por: Logan, Connor, et al.
Publicado: (2022)

Different Strategies for the Treatment of Age-Related Macular Degeneration in China: An Economic Evaluation
por: Wu, Bin, et al.
Publicado: (2016)

Faricimab for the Treatment of Diabetic Macular Edema and Neovascular Age-Related Macular Degeneration
por: Ferro Desideri, Lorenzo, et al.
Publicado: (2023)

Pharmacogenetics and Age-Related Macular Degeneration
por: Schwartz, Stephen G., et al.
Publicado: (2011)

Prevention of age-related macular degeneration
por: Wong, Ian Yat Hin, et al.
Publicado: (2010)

Angiogenin in age-related macular degeneration
por: Skeie, Jessica M., et al.
Publicado: (2011)

Pharmacotherapy for Age-Related Macular Degeneration
por: Ahmadieh, Hamid
Publicado: (2008)

Metabolomics and Age-Related Macular Degeneration
por: Brown, Connor N., et al.
Publicado: (2018)

Nanotechnology for Age-Related Macular Degeneration
por: Yang, Bo, et al.
Publicado: (2021)

Neuroprotection for Age-Related Macular Degeneration
por: Lin, Jonathan B., et al.
Publicado: (2022)

Age-Related Macular or Retinal Degeneration?
por: Gałuszka, Michalina, et al.
Publicado: (2023)

Age-related macular degeneration and the aging eye
por: Ehrlich, Rita, et al.
Publicado: (2008)

Age-Related Macular Degeneration and the Aging Brain
por: Whitson, Heather, et al.
Publicado: (2021)

Evaluation of variants in the selectin genes in age-related macular degeneration
por: Mullins, Robert F, et al.
Publicado: (2011)

Evaluation of real-world mobility in age-related macular degeneration
por: Sengupta, Sabyasachi, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_4vqjho7jo045v2df7hn7gkhj53